Vaxart, Inc.
170 Harbor Way
Suite 300
South San Francisco
CA
94080
United States
Tel: 650-550-3500
Website: http://www.vaxart.com/
Email: hr@vaxart.com
About Vaxart, Inc.
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury.
Vaxart has demonstrated that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication.
Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. All intellectual property is fully owned by Vaxart, without any encumbrances.
Stock Symbol: VXRT
Stock Exchange: NASDAQ
96 articles about Vaxart, Inc.
-
Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock
6/7/2023
Vaxart, Inc. announced the pricing of its underwritten public offering of 16,000,000 shares of its common stock, for gross proceeds of approximately $15,000,000, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Vaxart.
-
Vaxart, Inc. Announces Proposed Public Offering of Common Stock - June 06, 2023
6/6/2023
Vaxart, Inc. announced that it has commenced an underwritten public offering of its common stock.
-
Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate
6/6/2023
Vaxart, Inc. (Nasdaq: VXRT) today announced that the last subject has completed dosing in the Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate.
-
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
5/4/2023
Vaxart, Inc. announced its business update and financial results for the first quarter of 2023.
-
Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4
4/28/2023
Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2023 after the market close on Thursday, May 4, 2023.
-
Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6
3/29/2023
Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will make presentations at the World Vaccine Congress Washington 2023 in Washington, D.C. on Wednesday, April 5 and Thursday, April 6, 2023.
-
Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
3/17/2023
Vaxart, Inc. (NASDAQ: VXRT) today announced it will host a key opinion leader video webcast on the health and economic impact and disease burden for norovirus on Tuesday, March 28, 2023 at 1:00 p.m. ET.
-
Vaxart Provides Business Update and Full Year 2022 Financial Results
3/15/2023
Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the full year 2022, during which Vaxart announced it is prioritizing development of the Company’s bivalent norovirus candidate.
-
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
3/8/2023
Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2022 after the market close on Wednesday, March 15, 2023.
-
Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate
2/14/2023
Vaxart, Inc. (NASDAQ: VXRT) today announced that it has dosed the first subject in the Phase 2 clinical trial of its oral tablet bivalent norovirus candidate.
-
Vaxart Names Phillip Lee as Chief Financial Officer
12/19/2022
Vaxart, Inc. announced that it has appointed Phillip Lee as its Chief Financial Officer, effective immediately.
-
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
12/1/2022
Vaxart, Inc. (Nasdaq: VXRT) today announced it will commence a new study of Vaxart’s oral pill norovirus vaccine candidate focused on protecting breastfeeding mothers and their infants.
-
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29
11/22/2022
Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego on Tuesday, November 29, 2022 at 1:50 p.m. PT / 4:50 p.m. ET.
-
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
11/8/2022
Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the third quarter of 2022, during which the Company made significant progress on its oral vaccine candidates.
-
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8
10/20/2022
Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2022 after the market close on Tuesday, November 8, 2022.
-
Vaxart to Present at World Vaccine Congress Europe 2022 on October 13
10/10/2022
Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will make separate presentations at the World Vaccine Congress Europe 2022 in Barcelona, Spain on Thursday, October 13, 2022.
-
Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/7/2022
Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will be presenting virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.
-
Biopharma and life sciences companies, such as Seraxis, Verily and Vaxart, tap new members to bolster their leadership teams in roles like CMO, CTO, CCO, and more.
-
Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate
9/1/2022
Vaxart, Inc. reported positive top-line data from the first part of a planned two-part Phase II study of its Wuhan S-only oral pill COVID-19 vaccine candidate, VXA-CoV2-1.1-S.
-
Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial
8/31/2022
Vaxart, Inc. (Nasdaq: VXRT) today announced it will release top-line data from the first part of its planned two-part COVID-19 Phase II trial of its Wuhan S-only construct before the market open on Thursday, September 1, 2022.